Physician profile
Mitul Kanzaria
NPI 1639499023
$15,231.19
in general payments reported to CMS, 2019-2025
47 companies · $2,860 in 2025
The $2,860 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,844 · 2020: $1,449 · 2021: $1,642 · 2022: $2,266 · 2023: $2,704 · 2024: $2,468 · 2025: $2,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,031.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,475.00 | 2019-2025 | Avvigo Guidance System, Emerge Push, Mamba |
| Abiomed | $1,941.45 | 2020-2025 | Impella |
| Abbott Laboratories | $1,816.19 | 2019-2025 | Jot Dx, Esprit, Xience Skypoint |
| Astrazeneca Pharmaceuticals LP | $1,041.21 | 2019-2025 | Farxiga, Andexxa |
| Medtronic, INC. | $777.52 | 2021-2023 | Onyx Frontier, Micra, Launcher |
| Janssen Pharmaceuticals, INC | $719.74 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $678.52 | 2019-2024 | Eliquis, Camzyos |
| Amgen INC. | $662.94 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $524.97 | 2021-2025 | (6496) Fm Other, (5044) Mcot, Mcot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.53 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $365.88 | 2019-2024 | Lifevest |
| Pfizer INC. | $341.84 | 2019-2025 | |
| Shockwave Medical, INC | $318.64 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Novartis Pharmaceuticals Corporation | $279.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $161.42 | 2022-2023 | Verquvo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $156.93 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Penumbra, INC. | $155.26 | 2019-2025 | Ruby Coil, Penumbra System |
| Irhythm Technologies, INC. | $121.03 | 2020-2024 | Zio Monitor, Zio Xt Patch |
| Medtronic Vascular, INC. | $108.21 | 2019 | |
| Inari Medical, INC. | $103.23 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cardinal Health 200 LLC | $88.50 | 2019 | |
| W. L. Gore & Associates, INC. | $85.33 | 2019 | |
| Cardiovascular Systems INC. | $80.88 | 2019-2023 | Diamondback Peripheral |
| Becton, Dickinson and Company | $78.31 | 2024 | Venovo |
| Kestra Medical Technology Services, INC. | $73.89 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $71.79 | 2022-2023 | |
| Abbvie INC. | $62.45 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $61.84 | 2023-2024 | Inpefa |
| Cvrx, INC. | $58.52 | 2024-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $54.72 | 2022-2025 | Optimizer |
| Stryker Corporation | $45.25 | 2025 | Flowtriever |
| Chiesi USA, INC. | $37.57 | 2025 | Kengreal |
| Atricure, INC. | $37.13 | 2025 | Atriclip Laa Exclusion System |
| Lantheus Medical Imaging, INC. | $36.18 | 2023-2024 | Definity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.04 | 2024 | Xifaxan |
| Baxter Healthcare | $27.82 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $27.52 | 2022-2023 | Arcalyst |
| United Therapeutics Corporation | $25.85 | 2022-2023 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $19.31 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.00 | 2024 | Arcalyst |
| Novo Nordisk INC | $17.23 | 2024 | Wegovy |
| Althera Pharmaceuticals LLC | $17.17 | 2022 | |
| La Jolla Pharmaceutical Company | $17.14 | 2025 | Giapreza |
| Esperion Therapeutics, INC. | $15.43 | 2024 | Nexletol |
| Cordis US Corp. | $15.40 | 2022 | |
| Csl Behring | $11.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,015.43 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitul Kanzaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.